The regulation of water and electrolyte homeostasis is multifactorial and includes the heart and kidneys as important regulatory centers. Within the heart, a recently discovered hormone, atrial natriuretic factor (ANF), has been implicated in the maintenance of water and salt balance. Primarily found in mammalian atria, ANF 
Introduction
The regulation of water and electrolyte homeostasis is under multifactorial control; some factors are responsible for the behavioral patterns of water and salt intake, while others are involved in the regulation of fluid and electrolyte retention of excretion (1) . Many organs, including the heart, contribute to the maintenance of water and salt balance. Within the heart, atrial natriuretic factor (ANF),' a 28 amino acid peptide hormone that is released from atria after activation of stretch receptors, and perhaps other hormonal signals, appears to play an important role in the regulation of water and electrolyte balance in concert with other hormonal systems such as renin, angiotensin, aldosterone, and vasopressin (2, 3) . First isolated from mammalian atria, ANF has also been found, albeit at much lower levels, in other tissues including ventricles, brain, pituitary, adrenals, and lungs (4) . The presence of ANF prohormone (5) and mRNA (6) in normal rat lungs, together with our observation that rat lungs secrete biologically active ANF (5) , suggest that lungs may be a physiologically relevant source of circulating ANF under certain conditions. We tested this hypothesis using genetically cardiomyopathic hamsters, a model of human congestive heart failure and a paradigm of hereditary dystrophy-like cardiopathy and myopathy (7) . Cardiomyopathic hamsters have been shown to be deficient in atrial ANF bioactivity (8) with a corresponding reduction in ANF mRNA levels (9) , suggesting that ANF gene expression is deficient in the atria of these animals. Paradoxically, plasma ANF levels are markedly increased (10). These data cannot be reconciled solely by an increased secretion leading to a subsequent reduction in storage in the atria (1 1). These observations suggest that an extra atrial source of ANF may develop during congestive heart failure. One such source appears to be the ventricular myocardium (12) . In this study we show that the lung may be another, and particularly important, source.
Methods
Animals. The cardiomyopathic hamsters (TO.2) used in this study were originally derived from BIO 53.58 cardiomyopathic hamsters (13) After 20 min centrifugation at 32,000 g the pellet was washed and rehomogenized in 2.5 acetic acid containing inhibitors. Both supernatants were collected together. Right and left atria were also quickly dissected and separately collected in 2 ml 0.1 M acetic acid with inhibitors. The same procedure as described for lungs was followed. The ANF immunoreactivity was determined by direct RIA as previously described (14) .
Extraction of ANF from plasma and tissues. After decapitation, trunk blood was collected in chilled tubes containing 1 mg EDTA, 10 MI pepstatin A 0.5 10-3 M, and 10 Ml PMSF l0-3 M/ml of blood and centrifuged at 3,500 rpm for 20 min at 4VC. The plasma was assayed immediately or stored at -700C. The ANF was extracted from plasma by heat-activated glass beads (Vycor; Corning Glass Works, Corning, NY) (15) . To 1 ml of hamster plasma, 0.5 ml ofactivated glass suspension (Vycor; 50 mg in 1 ml distilled water) was added and agitated slowly in a cold room (40C) for 30 min. After 3 min centrifugation at 3,000 rpm the supernatant was aspirated and the glass powder was washed with 1.5 ml deionized water. The adsorbed ANF was eluted from the glass powder with 1 ml of 60% acetone in 0.05 M HCl. The acetone was evaporated in a nitrogen stream and the aqueous phase was lyophilized in a Speed-Vac. Just before the assay the residue was dissolved in RIA buffer.
For further purification on reverse phase (RP)-HPLC, tissue ANF was extracted from homogenates on Sep-Pak cartridges that were activated by 8-10 ml acetonitrile and then washed with 8-10 ml ammonium acetate, pH 4.0. The adsorbed ANF was eluted with 3 ml 60% acetonitrile in ammonium acetate (0.2%, pH 4.0). The organic solvent was evaporated under a nitrogen stream followed by lyophilization in a Speed-Vac (16) .
RIA forANF. ANF immunoreactivity was determined by a double antibody RIA (14) . The sensitivity of this assay was -0.75 pg.
Reverse phase HPLC. The lyophilized tissue extracts were dissolved in 10% acetonitrile and 0.1% trifluoroacetic acid (TFA) and injected on a C18,gm Bondapak column (3.9 mm X 30 cm) in a (LKB Instruments, Inc., Gaithersburg, MD) HPLC system. The elution of ANF from the column was performed with a linear gradient of 15-50% acetonitrile in 0.1 % TFA at a flow rate of 1 ml/min. The 2-ml fractions were collected. ANF immunoreactivity was determined by direct RIA (14) .
RNA analysis. Animals were killed by decapitation and lungs, ventricles, and atria were dissected and quickly frozen in liquid nitrogen. Measurements were performed on two groups, each consisting of 10 controls and 5 cardiomyopathic animals. Total RNA was extracted and processed for Northern blot hybridization as previously described (17) using a 32P-labeled 600-bp Pst I fragment of rat ANF cDNA (18) . The amount of total RNA was quantitated using ultraviolet spectroscopy, and the integrity ofthe RNA was checked by agarose gel electrophoresis. The amount of total mRNA in each RNA sample was evaluated by dot blot hybridization to a 32P-labeled oligo(dT)12 18 probe. Finally, a rat brain ,B-actin cDNA probe (19) was used as internal control in rehybridization experiments. The amount of specific mRNA species was quantitated by densitometric scanning ofthe autoradiographs. No significant change in the level of f and 'y actin mRNAs was observed among the different groups.
Hamster lungperfusion. Hamsters were anesthetized with an intraperitoneal injection of pentobarbital (1.6 mg/100 g body wt) after they were killed, and the lungs perfused according to the technique of Engineer et al. (20) as we have previously described. Briefly, the heart and lungs were totally removed and rapidly perfused with oxygenated Krebs buffer via pulmonary artery. The lungs were perfused initially at a rate of 10 ml/min and inflated several times to eliminate all traces of blood. After the cannula inside the pulmonary artery was tied, the heart was discarded and the lungs were then perfused at a rate of 2 ml/min. Collection of the effluent was started after a 5-min stabilization period. The perfusates were collected with an equal vol of 0.2 M acetic acid containing the protease inhibitors to give a final concentration of 1 mg EDTA/ml, 10 MM PMSF, and 5 MM pepstatin A. The ANF immunoreactivity was measured in the perfusate by RIA after prior extraction on Sep-Pak cartridges.
Radioreceptor assay. The biological activity of ANF isolated from hamster lung perfusate was assessed by radioreceptor assay using rat kidney glomerular membranes (21 
Results
ANF content in atria, lung, and plasma of cardiomyopathic and control hamsters. Pulmonary and atrial ANF were determined in homogenates by direct RIA (14) . Dilution curves of Fig. 2 , ANF mRNA in lung is not detectably changed in cardiomyopathic hamsters at the onset of development of hypertrophy (106 d old). With progression of the disease, ANF mRNA increased in the lung; in cardiomyopathic animals who have developed cardiac hypertrophy but are not in congestive heart failure, pulmonary ANF mRNA increased twofold. Lung ANF mRNA was greatest (fivefold increase over control) in animals (272 d old) who were in congestive heart failure. In contrast, atrial ANF mRNA levels are slightly decreased (40%) in the same cardiomyopathic animals as compared with the controls, while ventricular ANF mRNA is significantly increased as previously reported (9) .
Hamster lung perfusion. To examine the secretion of ANF from lungs, the perfusion of this organ was performed. As shown in Fig. 3 A, ANF was released in a time-dependent manner during a 60-min perfusion of cardiomyopathic and normal hamster lungs. The HPLC pattern ofcardiomyopathic hamster lung perfusates was identical to the pattern of plasma ANF (Fig. 3 B) . We further tested the biological activity of lung-produced ANF by its ability to displace I25I-ANF from rat glomerular receptors (21) . The ANF purified from cardiomyopathic hamster lung perfusates did indeed compete in a dose-dependent manner with '25I-ANF for rat glomerular receptors (Fig. 4) , suggesting that it possesses the potential for full biological activity. 
Discussion
The results presented in this paper clearly show that lungs synthesize an increased amount of authentic ANF in a model of genetic cardiomyopathy, particularly during the development of congestive heart failure. During the development of disease, atrial ANF synthesis is diminished while plasma ANF is increased. This is accompanied by an increased content of lung ANF. Our study of the molecular forms of ANF present in the lungs shows that the main form is a 126 amino acid prohormone (Asn 1-Tyr 126). Since the circulating peptide is mainly a 28 amino acid fragment, the presence of a large proportion of prohormone in lungs rules out the possibility that increased pulmonary ANF content is simply due to increased In the lung of animals with congestive heart failure, ANF mRNA and peptide concentrations are 100-fold lower than in atria; however, since the mass of lung tissues is at least 50-fold greater than atrial tissues, the lungs may produce amounts of ANF similar to those produced in atria and thus contribute to the elevated levels of plasma ANF in these animals. The observation that authentic ANF can be secreted from lungs strengthens this hypothesis. It is important to mention that ANF gene expression is increased also in the ventricles of cardiomyopathic hamsters (12) . However, the exact contribution of ventricles to plasma ANF remains to be established and the physiological significance of increased ANF mRNA in diseased ventricles is being investigated.
The differential control of ANF gene expression in atria and extraatrial tissues, particularly in lungs, is intriguing and may be attributed to a differential response of the two tissues to changes in hormonal and neuronal activities. Indeed, the early phase of congestive heart failure is associated with increased sympathetic activity (23) and a reduced capacity to excrete water or salt (24) that may be due to impairment of cardiac ANF secretion. The increase in pulmonary ANF production may be a compensatory response to sympathetic stimulation and to the decrease in atrial ANF secretion. This response may play a protective role in preventing further increases in peripheral vascular resistance by increasing the level of plasma ANF.
Alternatively, stimulated synthesis of ANF in the lungs may have a physiologically important paracrine function in preventing pulmonary edema that develops in conditions of congestive heart shock, renal disease, and lung infections. In support of this hypothesis, two studies have recently shown that administration of ANF can prevent experimentally induced pulmonary edema (25, 26). Thus, during cardiac dysfunction, extraatrial tissues like lungs may play an integral part in regulating body fluid volume and electrolyte balance by increasing their production and secretion of biologically active ANF. This is a first observation of metabolic changes in the lungs in experimental cardiomyopathy. 
